MINNEAPOLIS, May 10 /PRNewswire-FirstCall/ -- Uroplasty, Inc. announced today Aetna’s national insurance coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) therapy for the treatment of overactive bladder (OAB) symptoms. Uroplasty’s Urgent(R) PC Neurostimulation System is the only device available to deliver PTNS.
Aetna, with 15 million members, is one of the nation’s leading providers of healthcare benefits. Daniel G. Holman, President and CEO of Uroplasty, commented, “We are pleased to learn of Aetna’s insurance coverage decision. Aetna’s policy, in combination with prior coverage decisions by Blue Cross Blue Shield of Minnesota, Blue Cross Blue Shield of Maryland, and reimbursement by numerous other payers, significantly expands patient access to PTNS therapy, a non-drug, non-surgical therapy for treatment of OAB symptoms.” Aetna joins the growing list of insurers that recognize the clinical benefit and cost-effectiveness of PTNS therapy for treating OAB symptoms.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions, including urinary and fecal incontinence, overactive bladder and vesicoureteral reflux.
The Urgent PC system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to the symptoms of overactive bladder. Uroplasty sells the Urgent PC system in the United States, in Canada and in countries recognizing the CE mark. Outside the United States, the Urgent PC is also indicated for the treatment of fecal incontinence
The I-STOP(TM) Mid-Urethral Sling is a biocompatible, tension-free sling used to treat female urinary incontinence. The I-STOP sling provides a hammock-like support for the urethra to prevent urine leakage associated with activities such as coughing, laughing, lifting or jumping. Uroplasty sells the I-STOP Sling in the United Kingdom and in the United States.
Macroplastique(R) Implants, Uroplasty’s patented soft tissue bulking agent, is used to treat both female and male urinary incontinence and to treat vesicoureteral reflux in children. When Macroplastique is injected into tissue, it stabilizes and “bulks” the tissue, providing the surrounding muscles with increased capability to control the flow of urine. Additionally, Uroplasty markets soft tissue bulking agents for specific indications such as PTQ(TM) Implants for the treatment of fecal incontinence, VOX(R) Implants for the treatment of vocal cord rehabilitation and Bioplastique(R) for augmentation or restoration of soft tissue defects in plastic surgery indications. Uroplasty’s bulking products are sold outside the United States.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements. This press release contains forward-looking statements, which reflect our views regarding future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, including those identified below, which could cause actual results to differ materially from historical results or those anticipated. The words “aim,” “believe,” “expect,” “anticipate,” “intend,” “estimate” and other expressions, which indicate future events and trends, identify forward-looking statements. Actual future results and trends may differ materially from historical results or those anticipated depending upon a variety of factors, including, but not limited to: the effect of government regulation, including when and if we receive approval for marketing products in the United States; the impact of international currency fluctuations on our cash flows and operating results; the impact of technological innovation and competition; acceptance of our products by physicians and patients, our historical reliance on a single product for most of our current sales; our ability to commercialize our recently licensed product lines; our intellectual property and the ability to prevent competitors from infringing our rights; the ability to receive third party reimbursement for our products; the results of clinical trials; our continued losses and the possible need to raise additional capital in the future; our ability to manage our international operations; our ability to hire and retain key technical and sales personnel; our dependence on key suppliers; future changes in applicable accounting rules; and volatility in our stock price.
FOR FURTHER INFORMATION: visit Uroplasty’s web page at http://www.uroplasty.com or contact Mr. Holman.
UROPLASTY, INC. Daniel G. Holman, Interim President and CEO 5420 Feltl Road Minnetonka, MN 55343-7982 Tel: 952-426-6140 Fax: 952-426-6199 E-mail: dan.holman@uroplasty.com
Uroplasty, Inc.
CONTACT: Daniel G. Holman, Interim President and CEO, Uroplasty, Inc.,Tel: +1-952-426-6140, or Fax: +1-952-426-6199, or dan.holman@uroplasty.com
Web site: http://www.uroplasty.com/
